Changeflow GovPing Healthcare & Life Sciences Process for Producing Purified Rhabdovirus from...
Routine Notice Added Final

Process for Producing Purified Rhabdovirus from Cell Culture

Favicon for changeflow.com USPTO Patent Applications - Biotech (C12N)
Published
Detected
Email

Summary

The USPTO has published a patent application detailing a process for producing a purified rhabdovirus from cell culture, specifically oncolytic rhabdoviruses like vesicular stomatitis virus. The application, filed on August 21, 2025, outlines methods for both upstream and downstream processing.

Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

This document is a published patent application (US20260085294A1) from the USPTO concerning a novel process for producing purified rhabdoviruses from cell cultures. The invention focuses on oncolytic rhabdoviruses, particularly vesicular stomatitis virus, and includes methods for upstream and downstream processing, as well as pharmaceutical compositions containing the virus. The application was filed on August 21, 2025, and published on March 26, 2026.

While patent applications do not impose direct regulatory obligations on entities, this publication signals potential future developments in the biotechnology and pharmaceutical sectors. Companies involved in viral vector development, gene therapy, or oncolytic virus research should review this application to understand emerging technologies and potential intellectual property landscapes. No immediate compliance actions are required, but awareness of this patented process may inform R&D strategies and competitive analysis.

Archived snapshot

Mar 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

PROCESS FOR PRODUCING A PURIFIED RHABDOVIRUS FROM CELL CULTURE

Application US20260085294A1 Kind: A1 Mar 26, 2026

Inventors

Dethardt MUELLER, Alan Pardo GARCIA, Tanja Anneliese GREIN, Friedrich KAESS, Judy NG, Katharina PESTA, Sabrina SCHNEIDER, Jordan TURNBULL

Abstract

The present invention relates to the field of upstream and downstream processing and provides a process for producing a purified rhabdovirus from a cell culture, preferably a purified oncolytic rhabdovirus and in particular a vesicular stomatitis virus, including pharmaceutical compositions comprising the rhabdovirus.

CPC Classifications

C12N 7/00 C12N 2760/20221 C12N 2760/20252

Filing Date

2025-08-21

Application No.

19306563

View original document →

Named provisions

Abstract

Get daily alerts for USPTO Patent Applications - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
March 26th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
US20260085294A1

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing 3254.1 Biotechnology
Activity scope
Viral Vector Production Drug Manufacturing
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Research & Development
Topics
Biotechnology Medical Research

Get alerts for this source

We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!